TY - JOUR
T1 - Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma
T2 - Results of prospective trials
AU - Choi, I.
AU - Tanosaki, R.
AU - Uike, N.
AU - Utsunomiya, A.
AU - Tomonaga, M.
AU - Harada, M.
AU - Yamanaka, T.
AU - Kannagi, M.
AU - Okamura, J.
PY - 2011/1
Y1 - 2011/1
N2 - We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL) - a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.
AB - We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL) - a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.
KW - HTLV-1 proviral load
KW - adult T-cell leukemia/lymphoma
KW - allogeneic hematopoietic SCT
KW - reduced-intensity conditioning regimen
UR - http://www.scopus.com/inward/record.url?scp=78651371147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651371147&partnerID=8YFLogxK
U2 - 10.1038/bmt.2010.92
DO - 10.1038/bmt.2010.92
M3 - Article
C2 - 20400987
AN - SCOPUS:78651371147
SN - 0268-3369
VL - 46
SP - 116
EP - 118
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 1
ER -
